Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy.

Wu Y, Yan S, Lv Z, Chen L, Geng J, He J, Yu Q, Yin J, Ren G, Li D.

Technol Cancer Res Treat. 2014 Apr;13(2):169-75. doi: 10.7785/tcrt.2012.500356. Epub 2013 Jun 24.

PMID:
23819497
[PubMed - indexed for MEDLINE]
2.

Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.

Wei D, Sun N, Nan G, Wang Y, Liu HQ, Peeters B, Chen ZN, Bian H.

Hum Gene Ther. 2012 Jul;23(7):700-10. doi: 10.1089/hum.2011.207. Epub 2012 Apr 18.

PMID:
22372930
[PubMed - indexed for MEDLINE]
3.

Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.

Altomonte J, Marozin S, Schmid RM, Ebert O.

Mol Ther. 2010 Feb;18(2):275-84. doi: 10.1038/mt.2009.231. Epub 2009 Oct 6.

PMID:
19809404
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer.

Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y.

J Mol Med (Berl). 2010 Jun;88(6):589-96. doi: 10.1007/s00109-010-0605-6.

PMID:
20393691
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.

Chai Z, Zhang P, Fu F, Zhang X, Liu Y, Hu L, Li X.

Virol J. 2014 May 12;11:84. doi: 10.1186/1743-422X-11-84.

PMID:
24885546
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.

Bai F, Niu Z, Tian H, Li S, Lv Z, Zhang T, Ren G, Li D.

Immunol Lett. 2014 May-Jun;159(1-2):36-46. doi: 10.1016/j.imlet.2014.02.009. Epub 2014 Mar 7.

PMID:
24613899
[PubMed - indexed for MEDLINE]
7.

Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.

Fournier P, Bian H, Szeberényi J, Schirrmacher V.

Methods Mol Biol. 2012;797:177-204. doi: 10.1007/978-1-61779-340-0_13.

PMID:
21948477
[PubMed - indexed for MEDLINE]
8.

Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK.

J Virol. 2010 Apr;84(8):3835-44. doi: 10.1128/JVI.01553-09. Epub 2010 Feb 10.

PMID:
20147405
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Genetically engineered Newcastle disease virus for malignant melanoma therapy.

Zamarin D, Vigil A, Kelly K, García-Sastre A, Fong Y.

Gene Ther. 2009 Jun;16(6):796-804. doi: 10.1038/gt.2009.14. Epub 2009 Feb 26.

PMID:
19242529
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.

Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martínez-Sobrido L, Woo SL, García-Sastre A.

Cancer Res. 2007 Sep 1;67(17):8285-92.

PMID:
17804743
[PubMed - indexed for MEDLINE]
Free Article
11.

Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.

Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V.

Int J Oncol. 2005 Feb;26(2):431-9.

PMID:
15645128
[PubMed - indexed for MEDLINE]
12.

Tumor-targeted efficiency of shRNA vector harboring chimera hTERT/U6 promoter.

Zhang P, Chen Y, Jiang X, Tu Z, Zou L.

Oncol Rep. 2010 May;23(5):1309-16.

PMID:
20372845
[PubMed - indexed for MEDLINE]
13.

Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice.

Dai M, Liu J, Chen DE, Rao Y, Tang ZJ, Ho WZ, Dong CY.

Cancer Gene Ther. 2012 Feb;19(2):77-83. doi: 10.1038/cgt.2011.65. Epub 2011 Sep 30.

PMID:
21959967
[PubMed - indexed for MEDLINE]
14.

Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F, Hemminki A, Di Virgilio F, Gramantieri L, Negrini M, Sabbioni S.

PLoS One. 2013 Sep 12;8(9):e73964. doi: 10.1371/journal.pone.0073964. eCollection 2013.

PMID:
24069256
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.

Pühler F, Willuda J, Puhlmann J, Mumberg D, Römer-Oberdörfer A, Beier R.

Gene Ther. 2008 Mar;15(5):371-83. doi: 10.1038/sj.gt.3303095. Epub 2008 Jan 17.

PMID:
18200068
[PubMed - indexed for MEDLINE]
16.

Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.

Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, Huang WD, Qian QJ, Zhao FL, Liu XY.

Hum Gene Ther. 2011 Sep;22(9):1109-19. doi: 10.1089/hum.2010.219. Epub 2011 Apr 21.

PMID:
21361790
[PubMed - indexed for MEDLINE]
17.

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y.

Mol Cancer Ther. 2010 Oct;9(10):2761-9. doi: 10.1158/1535-7163.MCT-10-0090. Epub 2010 Sep 21.

PMID:
20858727
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.

Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V.

Cancer Gene Ther. 2005 Mar;12(3):295-303.

PMID:
15605075
[PubMed - indexed for MEDLINE]
19.

TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro.

Song DZ, Liang Y, Xiao Q, Yin J, Gong JL, Lai ZP, Zhang ZF, Gao LX, Fan XH.

Anat Rec (Hoboken). 2013 Oct;296(10):1552-60. doi: 10.1002/ar.22768. Epub 2013 Aug 19.

PMID:
23959779
[PubMed - indexed for MEDLINE]
Free Article
20.

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Vigil A, Martinez O, Chua MA, García-Sastre A.

Mol Ther. 2008 Nov;16(11):1883-90. doi: 10.1038/mt.2008.181. Epub 2008 Aug 19.

PMID:
18714310
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk